Tarsus Pharmaceuticals's total assets for Q1 2026 were $581.13M, an increase of 3.38% from the previous quarter. TARS total liabilities were $232.18M for the fiscal quarter, a 6.15% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.